权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Hybrid Nanoparticles in Imaging and Therapy of Prostate*

混合纳米颗粒在前列腺成像和治疗中的应用*

基本信息

批准号：
7916136
负责人：
Kattesh V Katti
金额：
$ 15万
依托单位：
UNIVERSITY OF MISSOURI-COLUMBIA
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-08-01 至 2011-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7916136
关键词：
Affinity Animal Model Animals Arts Binding Biological Bombesin Cancer Center Carbohydrates Cell surface Cells Characteristics Computers Core Facility Coupled Detection Development Diagnosis Dimensions Drug Kinetics Education Engineering Enhancers Exhibits Experimental Models Family suidae GRP gene Generations Goals Gold Gum Arabic Human Hybrids Image Image Enhancement Imaging Techniques Implant In Situ In Vitro Interdisciplinary Study Investigation Isotopes Label Lead Libraries Liquid substance Malignant Neoplasms Malignant neoplasm of prostate Mass Spectrum Analysis Measurement Membrane Metals Missouri Modality Modeling Mus Nanotechnology Neutron Activation Analysis Peptides Phase Plasma Production Property Prostate Prostate Cancer therapy Prostatic Neoplasms Proteins Protocols documentation Radioactive Reaction Research Research Infrastructure Research Personnel Resources Roentgen Rays SCID Mice Science Sepharose Site Specificity Staging Starch Study models System Techniques Testing Theoretical model Therapeutic Therapeutic Agents Tissues Tracer Transmission Electron Microscopy Treatment Efficacy Tumor Specific Peptide Ultrasonography Universities Veterinary Medicine Xenograft procedure absorption base cancer cell college combat conventional therapy design imaging modality in vivo innovation medical schools models and simulation molecular imaging nanoparticle nanoparticulate nanoscale nanoscience phantom model product development programs radiochemical receptor simulation tomography tumor tumor xenograft

项目摘要

DESCRIPTION (provided by applicant): The University of Missouri (MU) Cancer Nanotechnology Platform (CNP) is the culmination of long-standing interdisciplinary partnerships in departments within the School of Medicine, the College of Arts and Science, the College of Veterinary Medicine, the Ellis Fischel Cancer Center, the Missouri University Research Reactor and the College of Engineering. Our CNP's overarching goal focuses on developing hybrid gold nanoparticle-based molecular imaging agents and targeted therapeutic agents that are effective in the diagnosis and treatment of prostate cancer. The specific objectives of our CNP include the following: (i) Synthesize and use a library of gold nanoparticles (AuNPs) for conjugation with prostate tumor-specific bombesin peptides. Investigate the photophysical properties, dispersity, and size-dimension measurements on these gold nanoparticles. (ii) Investigate biolocalization, pharmacokinetics and in vivo profiles of AuNPs stabilized with starch, agarose, and arabinagalactan protein (gum Arabic) in pigs. We will optimize analytical protocols, using techniques of neutron activation analysis (NAA), atomic absorption and radiochemical analysis using Au-198 nanoparticulate tracer, for the accurate estimation of AuNPs/gold metal in tissues and biological fluids, (iii) Develop new theoretical models, computations and simulations for the interaction of AuNPs with cells, (iv) Investigate the utility of AuNPs and bombesin-conjugated hybrid AuNPs as image enhancers in computed tomographic (CT) and ultrasound (US) imaging of prostate tumors in SCID mice implanted with human prostate cancer xenografts and with experimental modeling, simulations and studies on anthropomorphic phantom models of prostate cancer, (v) Optimize production of nanoparticulate a-emitting Au-198/199 and their utility for designing and developing tumor-specific Au-198/199-nanoparticlelabeled bombesin peptides for prostate tumor therapy. These studies will validate that multiple atoms of fiemitting Au-198 isotope, characteristic of nanoparticulate gold, will deliver significantly higher therapeutic payload to tumor sites than any conventional therapy. The MU Nanoparticles Production Core Facility will serve as a research and production resource for the unhindered supply of AuNPs to all investigators within the CNP program. The CNP provides unique opportunities for professionals from diverse academic backgrounds to be involved in collaborative scientific interactions that further our interdisciplinary research, education and product development program. We will apply principles of nanoscience and nanotechnology to develop innovative molecular imaging and therapeutic approaches to combat prostate cancer.

描述(由申请人提供)：密苏里大学(MU)癌症纳米技术平台(CNP)是医学院、文理学院、兽医学院、埃利斯·费舍尔癌症中心、密苏里大学研究反应堆和工程学院各系长期跨学科合作的成果。我们CNP的首要目标是开发在前列腺癌诊断和治疗中有效的基于金纳米颗粒的混合型分子显像剂和靶向治疗剂。我们的CNP的具体目标包括：(I)合成和使用金纳米粒(AuNPs)库，用于与前列腺癌特异性蛙皮素肽的偶联。研究这些金纳米粒子的光物理性质、分散性和尺寸测量。(Ii)研究淀粉、琼脂糖凝胶和阿拉伯半乳糖蛋白(阿拉伯树胶)稳定的AuNPs在猪体内的生物定位、药代动力学和体内分布。我们将利用中子活化分析(NAA)、原子吸收和使用Au-198纳米粒子示踪剂的放射化学分析技术来优化分析方案，以准确估计组织和生物体液中的AuNPs/金金属，(Iii)开发新的AuNPs与细胞相互作用的理论模型、计算和模拟，(Iv)研究AuNPs和蛙胶结合的杂化AuNPs作为图像增强剂在植入人前列腺癌移植瘤的SCID小鼠前列腺肿瘤的CT和US成像中的应用，以及前列腺癌拟人模型的实验建模、模拟和研究，(V)优化纳米颗粒a发射Au-198/199的生产及其在设计和开发用于前列腺癌治疗的肿瘤特异性Au-198/199纳米颗粒标记蛙皮素肽方面的效用。这些研究将验证发射Au-198同位素的多个原子(纳米金的特征)将比任何传统疗法向肿瘤部位提供显著更高的治疗有效载荷。MU纳米粒子生产核心设施将作为研究和生产资源，为CNP计划内的所有研究人员畅通无阻地供应AuNPs。 CNP为来自不同学术背景的专业人士提供了参与协作科学互动的独特机会，这些互动促进了我们的跨学科研究、教育和产品开发计划。我们将应用纳米科学和纳米技术的原理，开发创新的分子成像和治疗方法来对抗前列腺癌。